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Background: Cannabis has been the most widely used illicit drug worldwide throughout many years. Reports from 
different countries indicate that the potency of cannabis preparation has been increasing, as well as the ratio of 
tetrahydrocannabinol/cannabidiol has been changing. The high consumption couple with the variable chemical profile of 
the drug is increasing gradually the interest in researching the cannabis plant. Methods: This article reviews available 
literature on the analytical methods currently used for the detection and quantification of cannabinoids in cannabis plant. 
The papers were screened by two independently researchers and following a pre-specified protocol. Results and 
Discussion: The systematic review of the literature allowed to include 42 citations on cannabis plant analysis and 
botanical aspects of cannabis. Conclusions: The analytical methods for cannabis material published in the included 
articles of this systematic review showed lack of relevant information of the development of methods on GC and LC 
analysis and the limits of detection and quantification of mass detectors. These information, on the methods of analysis, 
are essential and extremely important, since in the current scenario the analytical approach should consider the action of 
modulation CBD with THC, which alters the disruptive effects of the drug and also presents important pharmacological 
activity. 
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Introduction 
 
Cannabis sativa L. (cannabis) remains the most 
widely cultivated, produced, trafficked and consumed 
drug worldwide (1, 2). At the same time, the plant has 
been used over the centuries for medicinal purposes (2-
5), which results in controversial perception and 
opinion on its use. According to the “World Drug 
Report” published by UNODC (1), in the previous year, 
cannabis market development yielded an increased in 
the global seizures of 2% on cannabis resin and 4% on 
cannabis herb, which led to seizures of 1.433 and 5.834 
tons, respectively. 
Cannabis has over 500 identified chemicals in plant 
and around 100 of them are classified as (phyto) 
cannabinoids (5, 6). Analyses of the cannabinoids 
content and chemical profile in cannabis plants are 
extremely relevant, because both the medicinal effects 
and the adverse health effects may be associated with 
the potency and/or interplay of certain cannabinoids and 
other compounds (such as terpenoids) due to cannabis 
consumption (4, 5). In relation to forensic interest, the 
cannabinoids data may also assist in developing 
classification models to chemotypes, on distinction of 
the varieties, in establishing the growth period of the 
plant and in drug trafficking restraint (5, 7, 8). 
Although there are currently several well-
established methods available for chemical analyses of 
cannabinoids (9-11), the high variability of cannabis 
samples become the chemical profile interpretation very 
difficult. There is a need for adaptations of traditional 
methods of cannabis analysis in light of new scientific 
evidence regarding the plant and its plant metabolites, 
taking into account the pharmacological activity as a 
potential drug and as a drug of abuse for recreational 
use. The instrumental analysis that have been 
commonly used to analyze cannabinoids are gas 
chromatography (GC) and liquid chromatography (LC) 
(3, 12). The use of GC, generally coupled to flame 
ionization detection (FID) (9, 11) or mass spectrometry 
(MS) detection, allows the analysis of a large variety of 
cannabinoids with high resolution (8, 10, 13). For 
analyzing cannabinoids in their acid forms, LC is the 
preferred method. In addition, the compounds can be 
efficiently screened using ultraviolet (UV) or 
photodiode-array (PDA) detector (11, 14). Other 
methods have been used, as the genetic profile analysis 
(12). A genetic analysis, e. g. real-time polymerase 
chain reation (PCR), is an alternative method to 
chemical analysis, to examine forensic samples of 
cannabis in order to determine the tetrahydrocannabinol 
(THC) content (15, 16). 
A systematic review becomes important during 
the process of realization of a survey, since, before 
starting the practical part, it is fundamental to design the 
analysis based on already performed methods for that 
type of research. Thus, this study aims to conduct a 
systematic review to summarize published results 
concerning the methods available for cannabis plant 
analysis over the period 2010-2016. 
 
Methods 
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The systematic review produced was based on 
relevancy to the topics of cannabis plant analysis, 
profile of cannabis and methodology of cannabis 
analysis. The source used for guidance and to performe 
the present paper was the PRISMA guidelines (17). 
 
 
Search strategy 
 
A systematic literature search was carried out by 
consulting six electronic scientific databases: PubMed 
(MEDLINE), LILACS, Scopus, SciELO and Google 
Scholar, through July 2016 to August 2016. 
A combination of the following search terms was 
used: “cannabis”, “marijuana”, “cannabinoids”, 
phytocannabinoids”, “drug detection”, “analytical 
methods”, “plant” and “herbal”. The publication date 
was imposed as restriction to the retrieved articles: from 
2010 through August 2016. Manuscripts were limited to 
English, Portuguese and Spanish languages. 
 
 
Selection criteria 
 
The follow inclusion criteria were established: 1) 
original research papers published since 2010 until 
August 2016; and 2) papers which evaluate analysis in 
cannabis plant material as the population of interest.  
There were no limits for cannabis plants: 
preparations (herbal form - the leaves, flowering tops, 
and resin form – hashish, hash oil), chemotypes (fiber, 
intermediate or drug), phenotypes (genetic factors - 
alleles BT, BD, BC and B0, a mutant form of the BD 
locus), varieties (indica, sativa or ruderalis), gender 
(male, female or monoecious), geographic location and 
origin, cultivation methods (outdoor, indoor, cloning or 
pollination), grown conditions (soil, humidity, 
temperature and photoperiod), growth period at 
harvesting, sample conservation at the time of analysis, 
or modes of supplying (seized, purchased or cultivated). 
 
 
Search articles  
 
The selection process concerning the articles to 
perform the paper (Figure 1) was accomplished 
uniformly by two independent researchers. Thus, both 
researchers conducted the screening, the determination 
of eligibility and the inclusion or exclusion of the 
papers related to methodology analysis for cannabis 
plant to attende this systematic review. 
 In the initial screening it was evaluated all titles and 
abstracts which researchers consider relevant. Articles 
that completely or partially lacked clear data to the 
information within the topic headings, such as analysis 
concerning synthetic cannabinoids or papers that 
showed solely the cannabis seizures data were rejected. 
The review papers and monographic scientific 
publications were also excluded of this study. There 
were no divergent opinions between the reviewers in 
including or excluding studies to eligible the articles for 
the systematic review. 
 
 
Data set 
 
After the selection performed at all databases 
involved in the study, repeated files were deleted and 
the remaining papers were placed in a single folder. The 
papers identified as potentially relevant were 
thoroughly reviewed and accepted or excluded from the 
study through consensus, by the reviewers. 
 
Figure 1 Selection process of the articles. 
 
Results and Discussion 
 
Cannabis sativa L.: botanical aspects forensic view 
 
Although there is constant discussion regarding the 
botanical classification of cannabis (18-20) since it was 
first classified in 1753, by the Swedish botanist Carolus 
Linnaeus (Carl Von Linné), the "Recommended 
methods for the identification and analysis of cannabis 
and cannabis products" of the United Nations Office on 
Drugs and Crime considers that the plant has only one 
recognized specie, it is the Cannabis sativa L. 
(Linnaeus) (9, 18, 19). Other species reported for the 
genus (C. sativa subsp. sativa, C. sativa subsp. indica, 
C. sativa subsp. ruderalis, C. sativa subsp. spontanea, 
C. sativa subsp. kafiristanca) currently are recognized 
as subspecies of the C. sativa L. (9, 18-20). 
Furthermore, due to the difficulty of distinguishing 
the cannabis subspecies either in chemical terms or 
morphologically, given that cannabis presents 
continuous changes according to the environment and 
conditions in which it was planted, the designation C. 
sativa is considered suitable for all plants for the genus 
(9, 20). 
Cannabis is an annual plant, dicotyledonous, 
angiosperm, usually dioecious, with male and female 
flowers on separate plants, but can also be monoecious, 
comprising flowers of both sexes in a single plant. The 
stamens (male) are generally higher, but less robust than 
the pistils (female). Before the occurrence of the 
flowering, the gender of the cannabis plant is 
Databases: PubMed (MEDLINE), 
LILACS, Scopus, SciELO, Web of 
Science and Google Scholar.  
Languages: English, Portuguese and 
Spanish. 
Words: “cannabis”, “marijuana”, 
“cannabinoids”, phytocannabinoids”, “drug 
detection”, “analytical methods”, “plant” 
and “herbal”.  
Seach results combined from two 
independent researchers on basis 
of abstract = 80  
Article screened on basis of text = 65 
• Excluded = 15 
• Duplicated articles 
• Synthetic cannabinoid 
• Cannabinoids in water or biological 
samples 
• Reviews 
Conformity to the review inclusion 
criteria = 42 
• Excluded = 23 
• Confusing data 
• Missing data 
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indistinguishable, however, throughout the plant 
development each gender varies widely, and the 
difference among the male and female plant becomes 
evident. The roots are straight and can range from 0.2 to 
6 meters, though the majority of plants reach heights 
from 1-3 meters. Both the branching degrees, such as 
plant height, depends on hereditary and environmental 
factors and the manner of cultivation (9, 21, 22). 
The fruits of cannabis, usually referred to as seeds, 
are small dried nuts, botanically named achene. The 
fruit contains one seed consists of two cotyledons and 
the major part of its mass is rich in reserve substances. 
The weight of achenes is quite variable, from 2 to 70 
grams per 1,000 seeds. Typically, the seeds in 
monoecious varieties are smaller than in dioecious 
variety (21). The plant spreads from these seeds, which 
grow vigorously in sunny environments, with neutral to 
alkaline soils requiring nutrients and water in 
abundance. The pollen grains produced by male flowers 
require air currents to carry them to the female flowers, 
resulting in fertilization and consequent production of 
seeds (9, 21). 
The cannabis growth cycle can be divided into four 
phases: germination and emergence; vegetative stage; 
flowering and seed formation; and senescence. The 
vegetative phase can be divided into three phases: 
juvenile stage; photosensitive phase; and flower 
development phase (21, 23). Male plants cease the 
dissemination after producing millions of pollens and 
then died (9, 21). 
Because it is a short-day plant, the critical 
photoperiod of cannabis is the time of day which the 
seed is induced to flower in time when the juvenile 
stage be ready, corresponding to approximately 14 
hours (21, 23). Flowering plant usually begins when the 
darkness exceeds 11 hours a day and this flowering 
cycle ranges between 4 and 12 weeks, depending on the 
strain and environmental conditions (9, 23). Shorter 
days (longest nights) induce early flowering and 
consequently the plant to complete its life cycle. Thus, 
cannabis starts flowering when exposed to short days - 
12 to 14 hours (nights from 10 to 12 hours or more). 
However, a single interrupted night of darkness can 
disrupt and delay the maturation of flowering. 
Moreover, maintain one or two short days may induce 
flowering, which may be irreversible in early maturing 
varieties (23). 
After ripening seeds, they can be harvested, eaten by 
birds or rodents, or fall to the ground where they can 
germinate the following spring (9). The female plants 
produce several individual bunches of flowers, a large 
cluster on the upper torso and various small in each 
branch. Instead of setting the seeds in the first flowers, 
the female plants continue to produce additional flowers 
and these are covered by glands named trichomes 
containing a rich resin cannabinoids and terpenoids 
(22). 
Although the genetics of the plant determines that it 
becomes male or female, environmental factors 
including the diurnal light cycle, can change the gender 
of the plant (hermaphrodites). Natural hermaphrodite 
with both genders are generally sterile, but induced 
hermaphrodites can artificially have fully functional 
reproductive organs. Feminized seeds of cannabis are 
obtained from artificially hermaphroditic females 
lacking the male chromosome or by seed treatment with 
hormones or silver thiosulphate. Thus, the production of 
pistils (female) can also be obtained by seeds (9, 21, 
23). 
Over the years a wide variety of chemical 
constituents that are part of the various classes of 
natural products have been identified in C. sativa (24, 
25). Currently, more than 750 chemical constituents 
have been identified in the plant (25). Among these, the 
natural products are mono- and sesquiterpenes, 
flavonoids, steroids, nitrogen compounds, besides the 
cannabinoids, the class of metabolites with 
toxicological significance (24, 25). Of the total 
compounds identified to date, more than 100 are 
classified as cannabinoids (25), which are encountered 
only in cannabis plants (24, 25). 
The term "cannabinoids" refers to a group of C21 or 
C22 terpenophenolic compounds, including analogues 
and metabolites (24, 25). They are secondary 
metabolites with a predominantly nonpolar character 
and therefore poorly soluble in water. They are 
synthesized in secreting cells which are inside glandular 
trichomes (26, 27). These structures are present in 
greater proportion in the flowers and inflorescences 
(buds) female unfertilized prior to senescence (26, 28). 
Smaller amounts of cannabinoids are found in leaves, 
petioles and stems, and they are absent in the roots and 
seeds, since the seeds of cannabis are protected by 
bracts, forming structures called achenes. As a result, 
the latter plant organs do not contain cannabinoids (27, 
28). 
 
Cannabis material analyzed 
 
According to UNODC (1), cannabis is opposite in 
relation to other drugs, because although the number of 
being stable seizures, the number of users and 
dependence reported increases each year (1, 29). It 
suggests that in 23 of the 50 north american states in 
which the medicinal and/or recreational use cannabis 
moves a business equivalent to the tobacco industry, 
being treated as a commodity (30). In the last two 
decades, the ratio of THC/CBD (cannabidiol) increased 
in the seized marijuana and this is linked to increase of 
neurotoxicity and cases of drug dependence (31). 
Functional neuroimaging studies have reported 
increases in neural activity in regions that may be 
related to cannabis intoxication or change in mood and 
reduction in activity of regions related to cognitive 
functions impaired during acute intoxication (32). 
Studies showed that frequent use is associated with 
greater severity of dependence, triplicates the chance of 
developing psychotic episodes and increased risk of 
cardiovascular disease and lung cancer (33-35). 
Therefore, the knowledge and understanding of 
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cannabis and its compounds are very important to 
provide data for further researches and corroborate with 
the clinical findings about pontency of the drug. 
Furthermore, the results of analysis can provide 
similarities between samples, sources of interconnecting 
production and trafficking. So, the data set acquired 
from cannabis samples analysis may also provide 
informations which can trace ways to assist forensic 
experts and control the cannabis use. 
Cannabis is a complex plant that naturally contains 
cannabinoids groups, closely related terpenophenolic 
compounds, which can occur a huge variation in their 
quantitative ratios. When study cannabis samples, 
understanding how the cannabinoids are chemically 
related to each other is substantial, since changes in the 
cannabinoid profile might occur not only in the 
different chemotypes. The conditions during growing 
and storage, such as environmental factors of 
cultivation (climates and elevation of cultivated area), 
the development stage of the plant at harvest time as 
well as genetic characteristics of seed-stocks are 
important factors that influence in the high variability 
and chemical composition of cannabinoids contents in 
cannabis plants (6, 36). 
The progress in cannabis cultivation techniques have 
shown that stress conditions also increases the 
production of cannabinoids, besides have led to an 
increase in the potency and yield of cannabis. Advances 
including plantation using automated indoor lighting, 
ventilation, automated irrigation and fertilization and 
using selective breeding of certain strains of cannabis 
are some examples of the main techniques that have 
been used through of the last decade (36, 37). 
Chemical types of cannabinoids can be divided in 
three groups: I) cannabinoids produced by biosynthesis 
of the plant (acid cannabinoids); II) cannabinoids 
present in the plant resulting from natural 
decarboxylation of acid cannabinoids (neutral 
cannabinoids) under the influence of storage, light 
and/or heat, by losing the relatively unstable carboxyl-
group in the form of CO2; and III) cannabinoids 
occurring as artefacts by degradation products resulting 
from various influences, such as UV-light, oxidation or 
isomerization (38).  
The most common types of acid cannabinoids found 
in cannabis plant are tetrahydrocannabinolic acid 
(THCA), cannabidiolic acid (CBDA), cannabigerolic 
acid (CBGA) and cannabichromenic acid (CBCA) (5, 6, 
38). These acids can be converted to their neutral 
counterparts by decarboxylation to form Δ9-
tetrahydrocannabinol (Δ9-THC), cannabidiol (CBD), 
cannabigerol (CBG) and cannabichromene (CBC), 
respectively (6, 11, 36, 38). Degradation of Δ9-THC 
results in formation of cannabinoids breakdown 
products as cannabinol (CBN), produced by oxidative 
degradation (36-38) and Δ8-tetrahydrocannabinol (Δ8-
THC) transformed by isomerization (6, 38), while 
THCA can further degrade into cannabinolic acid 
(CBNA) and this to CBN (5, 38). The cannabinoids 
cannabicyclolic acid (CBLA) and cannabicyclol 
(CBLA) arise, respectively, by exposure of CBCA and 
CBC to UV-radiation, leading to crosslinking of two 
double bonds in the molecule (38). Figure 2 shows the 
relationships between the main cannabinoid types that 
are usually detected in cannabis plant. 
 
Methods of analysis 
 
Although the most usual instrumental methods for 
analysis of cannabinoids are still GC/FID and LC/UV, 
and even the use of thin layer chromatography (TLC) is 
accepted as a confirmatory method for the cannabinoid 
profile by UNODC (9), the requirements for an 
acceptable cannabis assay and the knowledge of 
cannabinoids present in plant have changed 
dramatically over the years resulting in a large number 
of laboratories using a diverse array of analytical 
methodologies. 
 
 
 
 
Figure 2 Relationships between the main cannabinoid types 
that are usually detected in cannabis plant as cannabinoids 
produced by biosynthesis, cannabinoids resulting from natural 
decarboxylation and cannabinoids as artefacts by degradation. 
CBC: cannabichromene; CBCA: cannabichromenic acid; 
CBD: cannabidiol; CBDA: cannabidiolic acid; CBG: 
cannabigerol; CBGA: cannabigerolic acid; CBL: 
cannabicyclol; CBLA: cannabicyclolic acid; CBN: 
cannabidiol; CBNA: cannabinolic acid; Δ8-THC: Δ8-
tetrahydrocannabinol; Δ9-THC: Δ9-tetrahydrocannabinol; 
THCA: tetrahydrocannabinolic acid. 
 
 
Gas Chromatography analysis 
 
GC is an appropriate method for cannabis profiles 
and chemical fingerprints, as it allows the identification 
of a large variety of cannabinoids with very high 
resolution, especially when coupled with MS (GC/MS). 
However, during the analysis the high temperatures 
required for sample vaporization before injection can 
result in decarboxylation of the acid cannabinoids to 
their corresponding neutral forms and the thermal 
degradation of some cannabinoids (13). Therefore, to 
quantifying cannabinoids by GC analysis is required to 
determine the total content of each cannabinoid (the 
sum of its acid and neutral form), because the thermal 
conversion of acid cannabinoids may be not complete, 
resulting in a nonrepresentative analysis of the cannabis 
samples (6, 13). 
To avoid the decarboxylation of acid forms, a time-
consuming derivatization before GC analysis must be 
performed (39), e.g. by silylation as the trimethylsilyl 
ethers. However, an effective derivatization yield for all 
components in a complex mixture is difficult to achieve 
(13) and may also occur the thermo-degradation of 
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derivatized cannabinoids in injector and/or column 
system (40). Whereas the cannabis plant mainly 
contains the acid forms of cannabinoids, GC analysis 
presents a limited value to establish the metabolic 
profile of a cannabinoid sample. Table 1 lists all the GC 
methods described in the articles included in this 
systematic review. 
 
Liquid Chromatography analysis 
 
An accurate manner to assay the cannabis 
composition is to use a method that does not involve 
thermal stress, such as LC (40). This technique allows 
the simultaneous detection of both acid and neutral 
cannabinoids with no need of derivatization. However, 
the complex composition of the cannabis material leads 
to an arduous perform to achieve the separation of 
major cannabinoids and significant peak overlap occurs. 
The use of LC coupled with MS (LC/MS) may assist to 
resolve cannabinoids of interest though LC/MS but does 
not allow characterization of an entire cannabis sample, 
merely the determination of specific analytes (13). 
Table 2 lists all the LC methods described in the articles 
included in this systematic review.  
 
Mass spectrometry detector and analysis 
 
MS is a technique that can be used as a detector, 
coupled to a chromatography system or the sample may 
be analyzed directly in MS, lacking the separation of 
compounds contained in the sample. The main MS 
objective, as a detector or a method of analysis is to 
identify an analyte, especially in the presence of other 
analytes, based on the measurement of the analyte ion 
mass, according to their different mass ratios/charge 
(m/z) (41, 42). Table 3 lists all the MS parameters used 
to identify cannabinoids, described in the articles 
included in this systematic review. 
Although the full analysis of a complete cannabis 
extract with a single HPLC method is hard, resulting in 
chromatographic overlap, the HPLC method may be 
routinely combined with a secondary analysis by GC. 
Similarly, the difficulty to analyze both the acid 
cannabinoids and neutral with a GC method due to the 
necessity of derivatizing the acid forms, the GC method 
may also be combined with a secondary analysis by 
HPLC. By combining these two techniques of analysis, 
all major cannabinoids could be effectively identified 
and quantified. 
Simultaneously to the methods presented in Table 1, 
Table 2 and Table 3, there are some additional 
techniques and approaches that can be applied to the 
analysis of cannabis products. Methods for the 
identification of marijuana include: botanical 
identification, microscopical examination of leaves 
(58), chemical screening tests (57-59), THC 
identification through biochemical methods (60), and 
the use of molecular sequencing to identify DNA 
sequence homology to reference marijuana samples 
(61-63). Besides that, there are some unusual techniques 
used for this proposital, such as Nuclear Magnetic 
Resonance and electronic nose systems (51, 54) 
The genetic analysis provides the opportunity to link 
products on the basis of their genetic profiles, which 
could be useful from an investigative point of view, e.g. 
to link producers, traffickers and consumers (9). The 
main technique used is the PCR for analysis of SNPs 
(15, 28), Inter-Simple Sequence Repeat (ISSR) (49, 61), 
STR (45, 62) or specific genes (16, 63). However, 
unlike humans, the DNA fingerprint may not 
necessarily be unique, as cloning of cannabis strains is 
quite common. Matching DNA profiles of two samples 
does not by itself prove that they come from the same 
plant, let alone the same grower (9). Moreover, the 
diferent subspecies, as all other environmental and 
nutritional parameters affect the genetic analysis (45), 
along with the fact that genetic analysis of cannabis 
samples is a relatively expensive technique and 
sometimes questionable (9). It is not recommended to 
only perform genetic testing for forensic purposes. 
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Table 1 GC methods described in the articles included in this systematic review. 
Reference Extraction method Solvent extraction Column GC conditions Cannabinoids Detector 
(3)  liquid-liquid 
hexane / ethyl acetate 
(6:4) 
HP-5MS (30 m, 0.25 mm i.d., 0.25 μm 
film thickness) with a stationary phase 
of 5% phenyl and 95% dimethyl 
polysiloxane 
Temperature program 
starts at 100 °C (hold 
for 1 min), increases to 
290 °C (at 20 °C/min) 
and holds for 10 min.  
CBD 
MS 
CBN 
THC 
(7)  liquid-liquid hexane 
HP-5ms (30 m, 0.25 mm i.d., 0.25 μm 
film thickness) 
Temperature program 
starts at 100 °C, 
increases to 260 °C (at 
10 °C/min) and holds 
for 10 min 
cannabinoid 1 
MS 
THV 
cannabinoid 2 
CBL 
CBD 
THC 
CBG 
CBN 
(8)   liquid-liquid hexane 
HP-5MS (30 m, 0.25 mm i.d., 0.25 
μm), 5% phenylmethylpolysiloxane 
Temperature program 
starts at 100 °C (hold 
for 1 min), increases to 
260 °C (at 10 °C 
min/min) and holds for 
10 min 
CBC 
MS 
CBD 
THC  
CBG 
CBN 
(10) liquid-liquid methanol 
HP–5MS (30 m, 0.25 mm i.d., 0.25 μm 
film thickness) 
Temperature program 
starts at 150 °C (hold 
for 1 min), increases to 
280 °C (at 10 °C/min) 
and hold for 5 min 
Δ8-THC 
FID  and  MS 
THCV 
CBC 
CBD 
THC 
CBG 
CBN 
(12)  liquid-liquid hexane 
HP-5MS (30 m, 0.25 mm i.d., 0.25 μm 
film thickness) 
Temperature program 
starts at 100 °C, 
increases to 260 °C (at 
10 °C/min) and holds 
for 10 min 
CBC 
MS 
cannabivarin 
CBD 
THC 
CBG 
CBN 
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(36) liquid-liquid methanol 
DB-1 (30 m, 0.32 mm i.d., 0.25 µm 
film thickness) 
Temperature program 
starts at 230 °C (hold 
for 7 min), increases to 
260 °C (at 10 °C/min) 
and holds for 2 min 
CBD 
FID 
THC 
CBN 
(37) liquid-liquid 
0.5 mg/mL 
tribenzylamine in ethanol 
HP 1 (25 m, 0.32 mm i.d., 0.52 mm 
film thickness) 
Temperature program 
starts at 250 °C (hold 
9.50 min) 
THC 
FID and MS CBD 
CBN 
(43) liquid-liquid 
100 mg of 4-androstene-
3,17-dione + 10 mL 
chloroform + 90 mL 
methanol 
DB-1 (15 m, 0.25 mm i.d., 0.25 µm 
film) 
Temperature program 
starts at 170 °C (hold 
for 1 min), increases to 
250 °C (at 10 °C/min) 
and holds for 3 min 
THC 
FID 
THCV 
CBD 
CBC 
CBG 
CBN 
(44) liquid-liquid ethanol 
DB5 (30 m, 0.25 mm i.d., 0.25 µm film 
thickness) 
 
Temperature program 
starts at 60 °C, 
increases to 240 °C (at 
3 °C/min) and holds 
for 5 min 
CBDV 
FID 
THCV 
CBD 
CBC 
CB(1) 
CBGM 
Δ8-THC 
THC 
CBG 
(44) liquid-liquid ethanol 
HP5 (30 m, 0.25 mm i.d., 0.25 µm film 
thickness) 
Temperature program 
starts at 60 °C, 
increases to 240 °C (at 
3 °C/min) and holds 
for 5 min 
CBDV 
MS 
THCV 
CBD 
CBC 
CB(1) 
CBGM 
Δ8-THC 
THC 
CBG 
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(45) liquid-liquid ethanol HP5ms (30 m) 
Temperature program 
starts at 80 °C (hold 1 
min), increases to 300 
°C (at 50 °C/min) and 
holds for 9.6 min 
THC MS 
(46) - - 
DB-1 (15 m, 0.25 mm i.d., 0.25 µm 
film) 
Temperature program 
starts at 170 °C (hold 
for 1 min), increases to 
250 °C (at 10 °C/min) 
THCV 
FID 
CBD 
CBC 
THC 
CBG 
CBN 
(47) liquid-liquid 
100 mg of 4-androstene-
3,17-dione + 10 mL 
chloroform + 90 mL 
methanol 
DB-1MS (15 m, 0.25 mm i.d., 0.25 µm 
film) 
Temperature program 
starts at 170 °C (hold 
for 1 min), increases to 
250 °C (at 10 °C/min) 
and hold for 3 min 
THC  
FID 
THCV  
CBC 
CBD 
CBG 
CBN 
(48) liquid-liquid ethanol 
DB5 (30 m, 0.25 mm i.d., 0.25 µm film 
thickness) 
Temperature program 
starts at 60 °C, 
increases to 240 °C (at 
3 °C/min) and holds 
for 5 min 
THCV 
FID 
CBD 
CBC 
unknown cannabinoid 
CBGM 
THC 
CBG 
CBN 
(48) liquid-liquid ethanol 
HP5 (30 m, 0.25 mm i.d., 0.25 µm film 
thickness) 
Temperature program 
starts at 60 °C, 
increases to 240 °C (at 
3 °C/min) and holds 
for 5 min 
THCV 
MS 
CBD 
CBC 
unknown cannabinoid 
CBGM 
THC 
CBG 
CBN 
 
 
(49) - - 
DB-1 (15 m, 0.25 mm i.d., 0.25 µm 
film) 
Temperature program 
starts at 170 °C (hold 
THCV 
FID 
CBD 
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for 1 min), increases to 
250 °C (at 10 °C/min) 
CBC 
THC 
CBG 
CBN 
(50)  liquid-liquid methanol 
DB-1 (30 m, 0.32 mm i.d., 0.25 µm 
film thickness) 
Temperature program 
starts at 230 °C (hold 
for 7 min), increases to 
260 °C (at 10 °C/min) 
and holds for 2 min 
CBD 
FID 
THC 
CBN 
 
CB(1): unknown cannabinoid; CBC: cannabichromene; CBD: cannabidiol; CBDV: cannabidivarin; CBG: cannabigerol; CBGM: cannabigerol monomethyl ether; CBL: cannabicyclol; CBN: 
cannabidiol; Δ8-THC: Δ8-tetrahydrocannabinol; THC: tetrahydrocannabinol; THCV: tetrahydrocannabivarin; FID: flame ionization detector; MS: mass spectrometry; 
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Table 2 LC methods described in the articles included in this systematic review. 
 
Reference 
Extraction 
method 
Solvent 
extraction 
Column Mobile phase 
Flow 
(mL/min) 
Cannabinoids Detector 
(4) liquid-liquid 
methanol / 
chloroform (9:1) 
C18 (3.5 μm, 150 
mm×4.6 mm i.d.) with a 
1 mm opti-guard C18 
precolumn 
solvent A: 50 mM ammonium formate buffer pH 3.75 
with 10% acetonitrile, 
solvent B: 90% acetronitrile; The gradient program: 0 
min, 70% B; 15 min, 90% B; 30 min, 90% B; 31 min, 
70% B and 40 min 70%. 
1.0  
CBDA 
DAD 
(272 nm) 
CBGA 
CBG 
CBD 
THCV 
CBN 
THCA 
THC 
CBC 
(5) liquid-liquid 
ethanol / 
chloroform (9:1) 
C8 (3 μm, 125 mm×4 
mm i.d.) with a guard 
column (3 μm depth 
filter × 4 mm) 
solvent A: methanol and solvent B: water with 0.1% of 
acid acetic). The gradient program: 50% A, increased 
to 90% A over 20 min, maintained at 90% A over the 
next 1.5 min, decreased to 50% A over the next 0.5 
min, and held at 50% 
0.7  
CBGA 
DAD 
(230 nm) 
THCA 
CBDA 
CBG 
THC 
CBD 
CBC 
CBN 
(6) liquid-liquid 
methanol / 
chloroform (9:1) 
C18 (5 μm, 250×2.1 
mm i.d.) protected by a 
C18 guard column (5 
μm, 10×2.1 mm i.d.) 
methanol / water 50mM of ammonium formate (pH 
5.19). The gradient program: 68% methanol, increased 
to 90.5% methanol over 25 min, then increased to 95% 
in 1min and maintaining for 3 min 
0.3  
CBDA 
DAD 
(211 nm) 
neutral 
CBGA 
CBD 
CBG 
THCA 
DAD 
(220 nm) 
acids 
CBN 
THC 
Δ8-THC 
(11) liquid-liquid 
hexane / ethyl 
acetate (9:1) 
100 RP-18 (5 μm) 
LiChroCart 125-4 
Triethylammoniumphosphate buffer pH 3.0 (25 
mmol/L in nanopure water) and acetonitrile: 36:64, in 
isocratic mode 
1.5 
THC UV 
(210nm) THCA 
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(13) 
liquid-liquid 
with soxhlet 
ethyl acetate 
CN 100Å (4.60 
mm×150 mm i.d., 5 
μm) 
methanol and acid potassium permanganate 
chemiluminescence; 10% methanol in the initial 
mobile phase composition. The gradient program: 0 to 
70% methanol over a gradient of 12 min followed by 3 
min of 100% metanol 
1.0 
 
CBV 
2D-HPLC: 
UV (220 nm) 
/ CL 
CBCV 
CBDV 
CBLV 
EC-C18 (4.60 mm×50 
mm i.d., 2.7 μm) 
methanol and acid potassium permanganate 
chemiluminescence; The gradient program: 0 to 100% 
methanol in 3 min followed by 3 min of 100% metanol 
CBGV 
CBN 
CBD 
CBL 
- 
Postcolumn acid potassium permanganate 
chemiluminescence was generated using custom-built 
manifold. The chemiluminescence reagent merged with 
the HPLC eluent at a T-piece junction and the light 
emitted from the reacting mixture was detected. 
1.2  
CBG 
CBE 
CBT 
CBNA 
CBCA 
CBDA 
CBLA 
CBGA 
(14) liquid-liquid 
methanol / n-
hexane (9:1) 
LiChroCart 125-4, 
LiChrospher 60, RP-
Select B, 5 μm, column 
holder: manu-CART 
“4” and pre column: 
LiChrospher 60, RP-
Select B, 5 μm,  
TEAP buffer 25 mmol/L in deionized water and 
acetonitrile: 36:64, in isocratic mode 
1.0  
CBD 
DAD  
(210 nm) 
CBN 
THC 
THCA 
(39) liquid-liquid 
methanol / 
chloroform (9:1) 
Onyx Monolithic (100 
mm×4.6 mm i.d.) 
methanol and water: 75:25, in isocratic mode 0.8  
CBD 
PDA 
(220 nm) 
CBN 
THC 
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(40) HTH ethanol 
EC-C18 (150mm×2.1 
mm  i.d., 2.7 μm) with a 
EC-C18 guard column 
(5×2.1 mm i.d., 2.7 μm) 
solvent A: water, 0.1% formic acid and solvent B: 
0.1% formic acid. The gradient program: 8 min 
isocratic hold at 66% B, gradient to 95% B 
over 4 min; 95% B maintained for 1 min 
0.5  
CBDVA 
DAD 
(200 - 400 
and 214 nm) 
CBDV 
CBDA 
CBGA 
CBG 
CBD 
THCV 
THCVA 
CBN 
THC 
Δ8-THC 
CBC 
THCA 
(51) liquid-liquid methanol 
C18 (5 μm, 150 
mm×2.1 mm i.d.) 
solvent A: water, 0.1% formic acid and solvent B: 
methanol, 0.1% formic acid. The gradient program: 
30% B, increased to 70% B in 1 min, then increased to 
90% B in 30 min 
0.25  
THCA-D3 
MS 
CBD 
CBG 
CBDA 
CBN 
THC 
Δ8-THC 
CBC 
THCA 
(52) CPE 
0.1 to 0.7 g 
Dowfax 20B102 
+ 0.2 g Na2SO4 
diluted to 10 mL 
with deionized 
water 
C18 (5 μm, 250×4.6 
mm i.d.) 
Acetonitrile and water, acidified with 2.5 M H2SO4 
(pH=1.8): 83:17, in isocratic mode 
1.0  THC 
UV (DAD) 
(231 nm) 
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(53) SFE 
CO2 as extraction 
solvent and 
ethanol (20%) 
as co-solvent. 
 
C18 (2.6 μm, 150 
mm×3 mm i.d.) with a 
guard column (0.5 μm 
depth filter×0.1 mm) 
 
solvent A: deionized water, 0.1% formic acid, and 
solvent B: methanol, 0.1% formic acid. The gradient 
program: 50% B increased to 80% B over the first min, 
held at 80% B until 11 min, increased to 95% B over 
the next 2 min, held at 95% B until 16 min, decreased 
to 50% B over the next 2 min, and held at 50% B until 
28 min 
0.25  
CBD 
MS/MS 
THCV 
CBG 
CBN 
THC 
THCA 
solvent A: water, 0.1% formic acid and solvent B: 
methanol, 0.1% formic acid. The gradient program: 
50% B, increased to 100% B over 15 min, held at 
100% B until 17 min, decreased to 50% B over the 
next 2 min, and held at 50 B until 22 min 
cannabicoumaric 
acid 
Q-ToF 
CBCA 
10-EtO-9-OH-Δ6a-
THC 
[(±)-4-AcO-CBC-C5 
CBGA 
CBGAM 
THCA-C4 
(54) liquid-liquid 
ethyl acetate / 
ethanol 40%; and 
methanol / 
metanol 70% 
5 phenyl (25 cm x 4.6 
mm i.d.) and C8 guard 
column 3.9 mm×20 
mm, 2/pkg 
solvent A water (TFA 0.1%), solvent B water-
acetonitrile (65:35, TFA 0.1%) and solvent C 
acetonitrile; The gradient program: solvent A 0 min 
70%, 10 min 60%, 38 min 40%, 40 min 5%, 55 min 
0%, 74 min 70% 
0.9  
CBDA 
DAD-UV  
(210-400 
nm) 
(257 nm) 
neutral 
(324 nm) 
acids 
CBGA 
CBG 
CBD 
C18 (4.6 mm×250 mm 
i.d., 5 μm) 
solvent B water-acetonitrile (65:35, TFA 0.1%) and 
solvent C acetonitrile; The gradient program: solvent 
B: 0 min 70%, 30 min 35%, 43 min 5%, 
48 min 70% 
CBN 
THC 
THCA 
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(±)-4-AcO-CBC-C5: 4-acetoxycannabichrome; 10-EtO-9-OH-Δ6a-THC: 10-ethoxy-9-hydroxy-Δ6a-tetrahydrocannabinol; CBC: cannabichromene;  CBCA: cannabichromenic acid; CBCV: 
cannabichromevarin; CBD: cannabidiol; CBDA: cannabidiolic acid; CBDV: cannabidivarin; CBDVA: cannabidivarinic acid; CBE: cannabielsoin; CBG: cannabigerol; CBGA: cannabigerolic 
acid; CBGAM: cannabigerolic acid A monomethyl ether; CBGV: cannabigerovarin; CBL: cannabicyclol; CBLA: cannabicyclolic acid; CBLV: cannabicyclolvarin; CBN: cannabidiol; CBNA: 
cannabinolic acid; CBT: cannabicitran; CBV: cannabivarin; CL: chemiluminescence; CPE: cloud point extraction; DAD: diode-array detector; Δ8-THC: Δ8-tetrahydrocannabinol; HTH: high 
throughput homogenization; MS/MS: tandem mass spectrometry; THC: tetrahydrocannabinol; THCA: tetrahydrocannabinolic acid; THCA-C4: tetrahydrocannabinolic acid-C4; THCA-D3: (±)-
11-nor-Δ9-THC carboxylic acid-D3; THCV: tetrahydrocannabivarin; THCVA: tetrahydrocannabivarinic acid; PDA: photodiode-array detector; Q-ToF: quadrupole-time-of-flight; SFE: 
supercritical fluid extraction; TEAP: triethylammoniumphosphate 1 M; TOF: time-of-flight; UV: ultraviolet.  
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Table 3 MS detector parameters used to identify cannabinoids, described in the articles included in this systematic review. 
 
Reference Detector Ionization mode Cannabinoid 
Quantifier 
ion (m/z) 
Qualifier ions 
(m/z) 
Limit of 
quantification 
(LOQ) 
Limit of 
detection 
(LOD) 
(3)  MS EI (70 V) 
CBD 231 174, 314 0.01% (w/w) 0.005% (w/w) 
CBN 295 238, 310 0.01% (w/w) 0.005% (w/w) 
THC 299 314, 231 0.01% (w/w) 0.005% (w/w) 
(7) MS 
electron multiplier voltage 
(1976 V), ion source (230 °C), 
quadrupole (150 °C) 
cannabinoid 1 231 314, 299, 271 
- - 
THV 271 286, 203, 243 
cannabinoid 2 231 314, 174, 243 
CBL 231 232, 274, 314 
CBD 231 174, 314, 299 
THC 299 314, 231, 271 
CBG 193 231, 123, 316 
CBN 295 238, 310, 223 
(8) MS - 
CBC 
- - - - 
CBD 
THC 
CBG 
CBN 
(10) MS EI (70 V) 
Δ8-THC 
- - - - 
THCV 
CBC 
CBD 
THC 
CBG 
CBN 
(12)  MS 
electron multiplier voltage 
(1200 V), ion source (230 °C), 
quadrupole (150 °C) 
CBC 231 174, 314, 299 
- - 
cannabivarin 267 282, 238, 223 
CBD 231 174, 314, 246 
THC 299 314, 231, 271 
CBG 93 231, 123, 316 
CBN 295 238, 310, 223 
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(13) TOF 
ESI positive mode, nitrogen (as 
drying gas: 7 mL/min, 350 °C) 
and (as nebulizer gas: 16 psi), 
capillary voltage (4.0 kV), 
vaporizer temperature (350 
°C), cone voltage (60 V) 
CBV 
- 
282.38 
- - 
CBCV 286.41 
CBDV 286.41 
CBLV 286.41 
CBGV 288.42 
CBN 310.43 
CBC 314.46 
CBD 314.46 
CBL 314.46 
CBG 316.48 
CBE 330.46 
CBT 346.46 
CBNA 354.44 
CBCA 358.47 
CBDA 358.47 
CBLA 358.47 
CBGA 360.49 
(37) MS - 
THC 
- - - - CBD 
CBN 
(45) MS - THC - - - - 
(51) MS 
ESI positive mode, ionization 
spray voltage (5.2 kV), 
turboIon spray (450 °C), 
nitrogen (as a turbo heating 
gas, nebulizing gas, and curtain 
gas) 
CBD 
- 
315.2, 193.2 
- - 
CBG 317.2, 193.2 
CBN 311.2, 223.2 
THC 315.2, 193.2 
Δ8-THC 315.2, 193.2 
CBC 315.2, 193.2 
ESI negative mode, ionization 
spray voltage (-4.5 kV), 
turboIon spray (450 °C), 
nitrogen (as a turbo heating 
gas, nebulizing gas, and curtain 
gas). For negative ionization, 
post-column addition of a 1% 
ammonia solution in the 
extract was utilized at a flow 
rate of 50 μL/min 
THCA-D3 346.2, 302.1 
CBDA 357.2, 339.2 
THCA 357.2, 313.2 
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(53) 
MS/MS 
APCI positive mode, capillary 
voltage (3500 V), vaporizer 
temperature (280 °C), nitrogen 
(7 L/min at 210 °C), nebulizer 
(32 psi) 
CBD 315.1 192.8 259.0 0.5 ng/mL 0.2 ng/mL 
CBG 287.1 165.0 231.0 0.5 ng/mL 0.05 ng/mL 
CBDA 317.2 293.0 123.0 0.5 ng/mL 0.02 ng/mL 
CBN 311.0 222.9 293.0 0.5 ng/mL 0.05 ng/mL 
THC 315.0 193.0 259.0 0.5 ng/mL 0.05 ng/mL 
Δ8-THC 315.1 193.0 259.1 0.5 ng/mL 0.2 ng/mL 
Q-ToF 
APCI positive mode, source 
(450 °C), capillary voltage (0.7 
kV), corona discharge (5 μA), 
nitrogen (as the desolvation: 
800 L/h) and (as cone gas: 20 
L/h), source temperature (120 
°C), desolvation temperature 
(300 °C) 
CBC - 373.2015 - - 
THCA - 359.2222 - - 
10-ethoxy-9-hydroxy-Δ6a-THC - 375.2535 - - 
4-acetoxycannabichrome - 373.2380 - - 
CBGA - 361.2379 - - 
CBGAM - 375.2535 - - 
THCA-C4 - 345.2066 - - 
(55) MS/MS 
LAESI positive, infrared laser 
(2940 nm), pulsed mode (10 
Hz) 
CBD 
- - - - 
THC 
(56) MS 
STELDI positive mode, laser 
power (20 μJ), 3 shots per step, 
collision-induced dissociation 
energy (30-50 eV) 
CBD-C4 
- 
301, 259, 181 
- - 
CBND 311, 201, 193 
CBN 311, 201, 193 
THC 
315, 297, 259, 
193, 181 
CBD 
315, 297, 259, 
193, 181 
CBC 
315, 297, 259, 
193, 181 
OTHC 329, 311, 193 
CBCON-C5 329, 311, 193 
CBGM 331, 201, 193 
CBCVA-C3 A 331, 201, 193 
CBDVA-C3 331, 201, 193 
Δ9-THCA-C 4 A and/or B 345, 193, 299 
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(57) FT-ICR MS 
ESI negative mode, infusion 
fow rate (5 mL/min), capillary 
voltage (3.0 kV), nebulizing 
temperature (250 °C), collision 
gas (nitrogen), ion 
accumulation (1 s), isolation 
window (1.0 - m/z units), 
collision energy (25-45%) 
CBD-C1 or Δ9-THCO-C1 
- 
257.1547 
- - 
CBN-C3 or CBVD-C3 281.1547 
CBE-C3, CBDV-C3, Δ9-THCV-C3 or 
2-methyl-2-(4-methyl-2-pentenyl-7- 
propyl-2H-1-benzopyran-5-ol 
285.1860 
CBN-C4 295.1703 
Δ9-THCOA-C1 A and/or B 301.1445 
CBCN-C3 303.1602 
DCBF-C5 307.1703 
CBN-C5, CBF-C5 or CBND-C5 309.1860 
Unknown 313.1809 
Δ9-trans-THC-C5, CBD, Δ8-trans-THC, cis-Δ9-
trans-THC-C5, CBL-C5 or CBC-C5 
313.2173 
OTHC 327.1966 
(E)-CBGVA-C3, CBCON-C5 or CBE-C5 329.2122 
CBEA-C3 B, CBDVA-C3 or Δ9-THCVA-C3 A 329.1758 
CBCN-C5 331.1915 
Unknown 331.2279 
CBCVA-C3 A or Δ9-THCA-C4 A and/or B 343.1915 
CBEA-C5 A and/or B 345.2071 
[CBNA – H]- 353.1758 
[CBDA-C5 – H]-, [Δ9-THCA-C5 A – H]-, 
[Δ9-THCA-C5 B – H]- or [CBLA-C5 A – H]- 
357.2071 
Unknown 359.2228 
(–)-6a,7,10a-trihydroxy-Δ9- 
tetrahydrocannabinol or 
(–)-cannabitetrol 
361.2020 
Unknown 367.1551 
Unknown 369.1707 
Δ9-THCA-A-8-one 371.1864 
Unknown 375.1813 
Unknown 377.1910 
Unknown 385.1657 
Δ9-THCA-A-COOH 387.1813 
8β,11-bis-hydroxy-Δ9-THC-A 389.1970 
Δ9-THCA + C2H2O 399.2177 
Dimer: 328 Da + 310 Da 637.3899 
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Dimer: 314 Da + 328 Da 641.4212 
Dimer: 326 Da + 328 Da 653.3848 
Dimer: 346 Da + 328 Da 673.4110 
Dimer: 354 Da + 328 Da 681.3797 
Dimer: 358 Da + 328 Da 685.4114 
Dimer: 390 Da + 328 Da 717.4008 
 
APCI: Atmospheric-pressure chemical ionization; C2H2O: ethenone; CBC: cannabichromene; CBC-C5: cannabichromene; CBCA: cannabichromenic acid; CBCN-C3: cannabichromanone-C3; 
CBCN-C5: cannabichromanone; CBCON-C5: cannabicoumaronone; CBCV: cannabichromevarin; CBCVA-C3 A: cannabichromevarinic acid A; CBD: cannabidiol; CBDA: cannabidiolic acid; 
CBDA-C5: cannabidiolic acid; CBD-C1: cannabidiorcol; CBDV: cannabidivarin; CBDV-C3: cannabidivarin; CBDVA-C3: cannabidivarinic acid; CBE-C3: (5aS,6S,9R,9aR)-C3-cannabielsoin; 
CBE-C5: (5aS,6S,9R,9aR)-cannabielsoin; CBEA-C3 B: (5aS,6S,9RS,9aR)-9,10-C3-cannabielsoic acid B; CBEA-C5 A and/or B: (5aS,6S,9R,9aR)-cannabielsoic acid A and/or B; CBF: 
cannabifuran; CBG: cannabigerol; CBGA: cannabigerolic acid; CBGAM: cannabigerolic acid monomethylether; CBGM: cannabigerol monomethyl ether; CBGV: cannabigerovarin; (E)-
CBGVA-C3: cannabigerovarinic acid A; CBL: cannabicyclol; CBL-C5: cannabicyclol; CBLA: cannabicyclolic acid; CBLA-C5 A: cannabicyclolic acid A; CBLV: cannabicyclolvarin; CBN: 
cannabidiol; CBN-C5: cannabinol-C5; CBNA: cannabinolic acid; CBN-C3: cannabivarin; CBN-C4: cannabinol-C4; CBND: cannabinodiol; CBND-C5: cannabinodiol; CBT: cannabicitran; 
CBV: cannabivarin; CBVD-C3: cannabinodivarin; DCBF-C5: dehydrocannabifuran; Δ9-trans-THC-C5: (−)-Δ9-trans-(6aR,10aR)-tetrahydrocannabinol; Δ8-trans-THC: (−)-Δ8-trans-
(6aR,10aR)-tetrahydrocannabinol; cis-Δ9-THC-C5: (−)-Δ9-cis-(6aR,10aR)-tetrahydrocannabinol; Δ9-THCA: Δ9-tetrahydrocannabinolic acid; Δ9-THCA-C4 A and/or B: Δ9-
tetrahydrocannabinolic acid-C4 A and/or B; Δ9-THCA A and/or B: Δ9-tetrahydrocannabinolic acid A and/or B; Δ9-THCA-A-COOH: Δ9-THCOA-C1 A and/or B: Δ9-tetrahydrocannabiorcolic 
acid A and/or B; Δ9-THCA A-COOH: 11-nor-9-COOH-Δ9-tetrahydrocannabinolic acid A; Δ9-THCO-C1: tetrahydrocannabiorcol; Δ9-THCV-C3: Δ9-tetrahydrocannabivarin; Δ9-THCVA-C3 
A: Δ9-tetrahydrocannabivarinic acid A; EI: electron-impact; 8β,11-bis-hydroxy-Δ9-THC-A: 8β,11-dihydroxy-Δ9-tetrahydrocannabinolic acid; Δ9-THCA-A-8-one: Δ9-tetrahydrocannabinolic 
acid A-8-one; ESI: electrospray ionization; FT-ICR MS: Fourier transform ion cyclotron resonance mass spectrometry; LAESI: laser ablation electrospray ionization; MS/MS: tandem mass 
spectrometry; m/z: mass-to-charge ratio; OTHC: 10-Oxo-Δ6a(10a)-tetrahydrocannabinol; Q-ToF: quadrupole-time-of-flight; STELDI: laser desorption ionization; THC: tetrahydrocannabinol; 
THCA: tetrahydrocannabinolic acid; THCV: tetrahydrocannabivarin; TOF: time-of-flight. 
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Conclusions 
 
The analytical methods for cannabis material 
published in the articles included in this systematic 
review showed the need to update the methodologies 
regarding the new potency of the drug, whether for its 
pharmacological potential, improvement of clinical 
conduct or quantification in forensic science. Although 
the findings of the literature review refer to an increased 
difficulty in cannabinoid separation by LC analysis than 
by GC analysis, the mass detector provides 
unambiguous identification of different overlapping 
compounds according to those described in the 
systematic articles included in this systematic review. In 
addition, it was possible to show that GC analysis are 
more used.  
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